Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Restructuring Costs (2022 - 2023)

Historic Restructuring Costs for Ani Pharmaceuticals (ANIP) over the last 3 years, with Q2 2023 value amounting to $2000.0.

  • Ani Pharmaceuticals' Restructuring Costs fell 9992.22% to $2000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was $2000.0, marking a year-over-year decrease of 9997.06%. This contributed to the annual value of $1.1 million for FY2023, which is 8006.69% down from last year.
  • As of Q2 2023, Ani Pharmaceuticals' Restructuring Costs stood at $2000.0, which was down 9992.22% from $1.1 million recorded in Q1 2023.
  • Ani Pharmaceuticals' 5-year Restructuring Costs high stood at $2.6 million for Q2 2022, and its period low was $2000.0 during Q2 2023.